89bio stock trades near its 52-week high after 38.43 percent YTD gains

89bio stock stood at USD 14.84 on Nasdaq on September 19, 2026, 1.46 percent below its 52-week high of USD 15.06. The stock had gained 38.43 percent year to date, putting the clinical-stage biotech close to the upper end of its 52-week range.

Stock remains near yearly high

The price comparison is the clearest market signal. At USD 14.84, 89bio was USD 0.22 below the USD 15.06 high and USD 10.68 above the USD 4.16 low recorded across the same 52-week period.

The company carried a market capitalization of USD 2.20 billion as of September 19, 2026. The combination of a 38.43 percent YTD advance and a position 1.46 percent below the yearly high leaves the stock closely tied to expectations for clinical progress rather than established product sales.

Pegozafermin drives the thesis

89bio describes itself as a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. Its lead candidate, pegozafermin, is a glycoPEGylated analog of FGF21 being developed for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.

The investment case therefore depends on future clinical and regulatory milestones. The market capitalization of USD 2.20 billion is an equity value assigned to that pipeline, while the absence of commercial revenue makes conventional sales-based valuation less useful for the company at this stage.

Nasdaq price sets the checkpoint

For investors, the technical checkpoint is defined by the USD 15.06 52-week high and the USD 14.84 price on September 19, 2026. A move above the high would establish a new 52-week reference level, while the 38.43 percent YTD gain shows how far the stock has already moved from its 2025 year-end starting point.